$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The launch time and indications of brigatinib/brigatinib in the country
2026-02-01 22:25:32
Check Details
Detailed instructions for Entrectinib/Luo Shengquan
2026-02-01 22:25:32
Check Details
Is acotinib/acalabrutinib officially launched in China and when will it be launched?
2026-02-01 22:25:32
Check Details
What’s the latest news on ibrutinib/ibrutinib prices in 2025
2026-02-01 22:25:32
Check Details
Ruxolitinib tablets/number of tablets in a bottle of Jekvi
2026-02-01 22:25:32
Check Details
The pharmacological effects and main effects of clofazimine/sempra
2026-02-01 22:25:32
Check Details
Research progress on the efficacy of brigatinib/brigatinib (Embry) combined with Erbitux
2026-02-01 22:25:32
Check Details
Entrectinib cost per month
2026-02-01 22:25:32
Check Details
Is acotinib/acalabrutinib currently covered by medical insurance?
2026-02-01 22:25:32
Check Details
What is the difference between ibrutinib/Eco and zanubrutinib?
2026-02-01 22:25:32
Check Details
Is ruxolitinib tablets/ruxolitinib covered by medical insurance?
2026-02-01 22:25:32
Check Details
Guidelines for coadministration of clofazimine/semprol and cycloserine
2026-02-01 22:25:32
Check Details
1
2
...
2035
2036
2037
2038
2039
2040
2041
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
2
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
3
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
4
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
5
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
6
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
7
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
8
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
9
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management
10
Lemborexant: A Dual Orexin Receptor Antagonist Revolutionizing Insomnia Treatment
11
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
12
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial